Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2011;17:1528–36.

Article  Google Scholar 

Konuma T, Kato S, Oiwa-Monna M, Ishii H, Tojo A, Takahashi S. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies. Leuk Lymphoma. 2016;57:2126–32.

Article  CAS  PubMed  Google Scholar 

Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, et al. Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation. JAMA Oncol. 2020;6:e192974.

Article  PubMed  Google Scholar 

Abraham R, Szer J, Bardy P, Grigg A. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transpl. 1997;20:773–7.

Article  CAS  Google Scholar 

Shaw PJ, Afify Z. Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect. Bone Marrow Transpl. 1999;23:632–3.

Article  CAS  Google Scholar 

Hori A, Kami M, Ohnishi M, Murashige N, Kojima R, Takaue Y. Feasibility of early tapering of cyclosporine following reduced-intensity stem cell transplantation for advanced hematologic or solid malignancies. Haematologica. 2005;90:1001–3.

PubMed  Google Scholar 

Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transpl. 2009;15:1376–85.

Article  CAS  Google Scholar 

Inamoto Y, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood. 2011;118:456–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Cai Y, Jiang J, Wan L, Bai H, Zhu J, et al. Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia. Ann Hematol. 2018;97:497–507.

Article  PubMed  Google Scholar 

Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood. 2001;98:3868–70.

Article  CAS  PubMed  Google Scholar 

Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS, et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica. 2003;88:315–23.

CAS  PubMed  Google Scholar 

Burroughs L, Mielcarek M, Leisenring W, Sandmaier BM, Maloney DG, Baron F, et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation. 2006;81:818–25.

Article  CAS  PubMed  Google Scholar 

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, et al. Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transpl. 2018;24:1022–8.

Article  CAS  Google Scholar 

DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, et al. Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2020;26:2075–81.

Article  CAS  Google Scholar 

Moore J, Hamad N, Gottlieb D, Bajel A, Ritchie D, Yeung D, et al. Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 study. Blood Adv. 2023;7:5554–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–20.

Article  CAS  PubMed  Google Scholar 

Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–30.

Article  CAS  PubMed  Google Scholar 

Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.

Article  PubMed  PubMed Central  Google Scholar 

Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transpl. 2016;22:330–8.

Article  Google Scholar 

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–84.

Article  PubMed  Google Scholar 

Konuma T, Kanda J, Yamasaki S, Harada K, Shimomura Y, Terakura S, et al. Single cord blood transplantation versus unmanipulated haploidentical transplantation for adults with acute myeloid leukemia in complete remission. Transpl Cell Ther. 2021;27:334.e1–11.

Article  CAS  Google Scholar 

Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Hirabayashi S, et al. Differential effect of graft-versus-host disease on survival in acute leukemia according to donor type. Clin Cancer Res. 2021;27:4825–35.

Article  CAS  PubMed  Google Scholar 

Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, et al. Effect of graft-versus-host disease on post-transplantation outcomes following single cord blood transplantation compared with haploidentical transplantation with post-transplantation cyclophosphamide for adult acute myeloid leukemia. Transpl Cell Ther. 2023;29:365.e1–11.

Article  CAS  Google Scholar 

Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N. Engl J Med. 2016;375:944–53.

Article  PubMed  PubMed Central  Google Scholar 

Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY, Tong J, et al. Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies. Bone Marrow Transpl. 2014;49:1063–9.

Article  CAS  Google Scholar 

Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, et al. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transpl. 2016;51:1588–93.

Article  CAS  Google Scholar 

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2:909–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ando T, Tachibana T, Tanaka M, Suzuki T, Ishiyama Y, Koyama S, et al. Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. Blood Adv. 2020;4:408–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konuma T, Kato S, Ooi J, Oiwa-Monna M, Ebihara Y, Mochizuki S, et al. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. Biol Blood Marrow Transpl. 2014;20:396–401.

Article  CAS  Google Scholar 

Konuma T, Kato S, Isobe M, Mizusawa M, Oiwa-Monna M, Takahashi S, et al. Reduced-toxicity myeloablative conditioning consisting of Fludarabine/Busulfan/Low-Dose total body irradiation/granulocyte colony-stimulating factor-combined cytarabine in single cord blood transplantation for elderly patients with nonremission myeloid malignancies. Biol Blood Marrow Transpl. 2019;25:764–70.

Article  CAS  Google Scholar 

Mizusawa M, Konuma T, Kato S, Isobe M, Shibata H, Suzuki M, et al. Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation. Int J Hematol. 2020;111:858–68.

Article  CAS  PubMed  Google Scholar 

Konuma T, Ooi J, Nagayama H, Tomonari A, Tsukada N, Kato S, et al. Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. Ann Hematol. 2022;101:177–89.

Article  CAS  PubMed  Google Scholar 

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

CAS  Google Scholar 

Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–9.